Bkt140
Bkt140 is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-X-C chemokine receptor type 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 2 | 2 | 2 | 1 | — | 6 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 1 | 2 | 1 | — | 5 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 2 | 5 | — | — | — | 5 |
| Adenocarcinoma | D000230 | — | — | 2 | 4 | — | — | — | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 4 | — | — | — | 4 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 4 | — | — | — | 4 |
| Myeloid leukemia | D007951 | — | C92 | 2 | 4 | — | — | — | 4 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 2 | — | — | — | 2 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 2 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | — | 2 | — | — | — | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 2 | — | — | — | 2 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 2 | — | — | — | — | 2 |
| Hematopoietic stem cell mobilization | D019650 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bkt140 |
| INN | motixafortide |
| Description | Bkt140 is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-X-C chemokine receptor type 4. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545348 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | DA9G065962 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CXCR4
CXCR4
Organism
Homo sapiens
Gene name
CXCR4
Gene synonyms
NCBI Gene ID
Protein name
C-X-C chemokine receptor type 4
Protein synonyms
CD184, CD184 antigen, chemokine (C-X-C motif) receptor 4, FB22, Fusin, HM89, LAP-3, LCR1, LESTR, Leukocyte-derived seven transmembrane domain receptor, Lipopolysaccharide-associated protein 3, LPS-associated protein 3, neuropeptide Y receptor Y3, neuropeptide Y3 receptor, NPYRL, SDF-1 receptor, seven transmembrane helix receptor, seven-transmembrane-segment receptor, spleen, Stromal cell-derived factor 1 receptor
Uniprot ID
Mouse ortholog
Cxcr4 (12767)
C-X-C chemokine receptor type 4 (P70658)
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
75 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use